Efficacy of a second interleukin-17 inhibitor in psoriasis patients

Abstract

Among the many biological treatments for psoriasis, interleukin-17 (IL-17) inhibitors are safe and highly effective. Despite this, sometimes it is necessary to change the treatment. The efficacy of an IL-17 inhibitor was evaluated in patients who had suffered primary or secondary failure to treatment with another IL-17 inhibitor. The clinical trials analyzed did not show differences in efficacy between patients who had never received treatment and those already medicated with another IL-17 inhibitor. In clinical practice, the efficacy is slightly lower in those already treated with biological drugs.